Scientists analyze HIV drug levels in kids to improve dosing
NCT ID NCT03194165
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study examined blood samples from 65 children aged 0 to 18 who were taking common HIV medications. The goal was to create computer models that show how these drugs behave in children, helping doctors adjust doses for each child's age, weight, and other factors. The research did not test new drugs but aimed to make existing treatments safer and more effective for kids.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- antiretroviral drugs (dolutegravir, raltegravir, rilpivirine, nevirapine, atazanavir, darunavir, ritonavir)
- What this could lead to
- If successful, this could help doctors give more accurate doses of HIV medicines to children based on age, weight, and other factors.
- What could go wrong
- This is a small, completed study that only looked at existing blood test data. It does not test a new treatment, so any dosing recommendations would need further validation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
65 people
The number who actually took part.
- Started
-
Jun 2017
- Finished
-
Jun 2022
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Minor patient treated by one or more antiretroviral and for which a blood test has been performed
- Ages
-
Up to 18 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Children from 0 to 18 years; * Treatment with one antiretroviral drug (s) studied (dolutegravir, raltégravir, rilpivirine, nevirapine, atazanavir, darunavir, ritonavir)); * Blood dosage of the drug (s) as part of their therapeutic follow-up in the Pharmacology laboratory of the Cochin hospital between 2007 and 2017 Exclusion Criteria: * Concentration too low below the limit of quantification (indicating an absence of medication * patient with doubt about compliance
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV infection are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cochin Hospital
Paris, Paris, 75014, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can remote counseling help people with HIV cut back on alcohol?
- Can a Once-Daily HIV pill with food match Twice-Daily dosing during TB treatment?
- Four weeks vs twelve weeks: can a shorter TB prevention course work?
- Can a phone app keep young people with HIV engaged in care?
- Massive Real-World database aims to map how chronic diseases interact
- How do HIV drugs behave when kidneys fail? study measures blood levels